Project Grant R21AG104127
Award Date 9/3/26
Completion Date 8/31/29
Dollars Obligated $699K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02142, USA
Similar Awards
- The National Institute on Aging awarded Exqor Technologies Inc. $999,176 on September 22, 2025, under the Aging Research program (CFDA 93.866) to develop non-radioactive nanoprobes for magnetic resonance imaging of tropomyosin receptor kinase B (TrkB) in Alzheimer's disease. The project addresses early detection of decreased TrkB expression, which is implicated in impaired neurogenesis, synaptic damage, and neuronal death in Alzheimer's disease. The recipient is developing a two-part...
- The National Institute on Aging awarded Boston University Medical Campus $110,228 in project grant funding on February 7, 2027, to develop and validate a novel cellular model of entorhinal cortex layer II vulnerability in Alzheimer's disease under the Aging Research program (CFDA 93.866). The project will develop in vitro models using induced pluripotent stem cells (iPSCs) and direct fibroblast conversion to generate entorhinal cortex layer II (ECII)-like neurons for studying Alzheimer's disease...
- The National Institute on Aging awarded $1,212,742 to the Sloan-Kettering Institute for Cancer Research on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate epichaperomes as a mechanism for restoring drug responsiveness in Alzheimer's disease. The research tests the hypothesis that epichaperome inhibition with PU-AD restores synaptic architecture and re-enables responsiveness to levetiracetam (LEV), a therapy whose efficacy depends on properly localized SV2A...
- The National Institute on Aging awarded The Johns Hopkins University $618,410 under the R21 (Exploratory/Developmental) grant mechanism on February 1, 2026, to develop a deep learning-based miniature microscope for imaging aging and Alzheimer's disease pathology in preclinical models. The project addresses imaging constraints in Alzheimer's disease research by creating hardware optimized to visualize neurovascular unit (NVU) changes—neural, vascular, and blood flow alterations—that occur early...
- The National Institute on Aging awarded The Jackson Laboratory $716,579 on December 15, 2025, under the Aging Research program (CFDA 93.866) to conduct genetic dissection of microglia functions in complement-mediated synapse loss in Alzheimer's disease. The award funds basic neuroscience research examining how microglia—the brain's resident macrophages—trigger neuronal synapse loss through complement cascade activation in Alzheimer's disease models. The project addresses three knowledge gaps:...
- The National Institute on Aging awarded Cellsight Technologies, Inc. $1.754 million on September 20, 2025, under the Aging Research program (CFDA 93.866) to characterize and validate [18F]F-ARAG, a positron emission tomography imaging agent, as a biomarker for detecting and quantifying intracerebral and systemic T cell activity in patients with Alzheimer's disease. The project addresses the inadequacy of current methods for studying T cell involvement in Alzheimer's disease in living patients....
- The National Institute on Aging awarded the University of California, Berkeley $549,260 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop advanced large language model-based AI tools that enhance precision in predicting Alzheimer's disease pathology and cognitive outcomes. The research addresses critical gaps in precision medicine for Alzheimer's disease, particularly the need to capture patient heterogeneity, accurately identify treatment candidates for...
- The National Institute on Aging awarded New York University $6.203 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to examine peripheral immune markers and vascular dysfunction as contributors to cognitive decline and Alzheimer's disease. The research integrates circulating biomarkers—platelet aggregation, neutrophil activity, and proteomic data—with advanced imaging to assess associations between vascular and immune dysfunction and cerebrovascular burden, amyloid...
- The National Institute on Aging awarded the University of Pittsburgh $619,577 on September 1, 2026, under the Aging Research program (CFDA 93.866) for statistical methods development in spatial proteogenomics data analysis applied to Alzheimer's disease research. The project develops computational and statistical methods to advance spatial proteogenomics analysis, which integrates spatially resolved protein and transcript information to examine cellular organization in brain tissue. In Aim 1,...
- The National Institute on Aging awarded $780,217 to the University of Connecticut Health Center on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct longitudinal imaging of prefrontal cholinergic dynamics and cognitive flexibility in an Alzheimer's disease model. The research combines chronic two-photon imaging, fluorescent acetylcholine reporting, in vivo beta-amyloid labeling, and cell-type-specific chemogenetic and optogenetic control to test whether amyloid-beta...